Glucolin5%

Glucolin 5% injection is marketed in a range of concentrations (for example, lower concentrations such as 5% or 10%, and higher, more concentrated solutions such as 25% or 50%), and the generic name alone does not identify a single specific concentration. Depending on the specific product's concentration, Glucolin 5% injection is used for:

• Treatment of acute, symptomatic hypoglycemia (low blood sugar), including insulin-induced hypoglycemia
• Source of fluid and carbohydrate calories for patients requiring intravenous nutrition support
• A base fluid used to reconstitute or dilute other injectable medicines, as directed by a healthcare professional

Contains Glucolin 5% (glucose) dissolved in water for injection, available in multiple concentrations such as 5%, 10%, 25%, and 50%, among others. The generic name alone does not identify a single specific concentration; exact strength, container size, and indication vary by product. Always confirm the exact concentration on the specific product's own label before use, since different concentrations are used for different clinical purposes and are not interchangeable.

Glucolin 5% injection is a sterile intravenous solution of glucose (Glucolin 5%) in water, used in hospital and clinical settings to treat low blood sugar, provide fluid and caloric support, or serve as a base fluid for other injectable medicines. It is marketed in a range of concentrations, and the specific strength used depends on the clinical purpose - more concentrated solutions are generally reserved for treating acute hypoglycemia, while lower concentrations are used for general fluid and calorie replacement.

Therapeutic Class: Intravenous carbohydrate/caloric replacement and antihypoglycemic agent

Glucolin 5% is readily metabolized by the body to provide energy, helping to spare protein and reduce ketosis when given in adequate amounts. When given intravenously, it raises blood glucose levels, which is the basis for its use in treating hypoglycemia, and provides a source of calories when oral or enteral nutrition is not possible or insufficient.

• Administered only by intravenous injection or infusion; concentrated solutions (such as 25% or 50%) must never be given intramuscularly or subcutaneously
• Obtain a blood glucose level before administering, where possible, though emergency treatment of suspected hypoglycemia should not be delayed to await results
• Administer through a secure intravenous line, with care to avoid extravasation, since concentrated Glucolin 5% solutions are hypertonic and can cause tissue irritation if they leak outside the vein
• Do not administer concentrated Glucolin 5% simultaneously with blood through the same infusion set, due to the risk of red blood cell clumping
• Inspect the solution visually for particulate matter or discoloration before use

Use of Glucolin 5% infusion in patients on insulin or other glucose-lowering medicines requires coordinated blood glucose monitoring, since Glucolin 5% will raise blood sugar and may need corresponding adjustment of diabetes medication. Glucolin 5% solutions should generally not be administered simultaneously with blood products through the same infusion line. Any additives introduced into a Glucolin 5% solution should be checked for compatibility by a pharmacist before use.

Possible adverse effects

• Hyperglycemia (raised blood sugar), particularly with rapid infusion or in patients with impaired glucose tolerance
• Fluid overload with prolonged or large-volume infusion
• Injection-site irritation, phlebitis, or thrombosis, especially with concentrated (hypertonic) solutions given through a peripheral vein
• Electrolyte imbalances, particularly low potassium, magnesium, or phosphate levels, with prolonged use

Serious reactions

Hypersensitivity and infusion reactions, including anaphylaxis, have been reported and require immediate discontinuation of the infusion and medical attention.

Pregnancy

Glucolin 5% injection is commonly used in pregnancy when clinically indicated, such as for treating hypoglycemia or providing fluid and caloric support, under medical supervision.

Breastfeeding

There is no specific concern regarding compatibility with breastfeeding for Glucolin 5% injection when used as directed by a healthcare professional in a monitored clinical setting.

• Use with caution in patients with known or subclinical diabetes mellitus, as Glucolin 5% infusion can raise blood glucose and cause hyperglycemia or glycosuria.
• Rapid or excessive infusion, particularly of concentrated Glucolin 5% solutions, can lead to hyperglycemia, and in severe cases coma; infusion rate should not exceed the patient's ability to metabolize the Glucolin 5% load.
• If a concentrated Glucolin 5% infusion is abruptly stopped, a lower concentration (such as 5% or 10% Glucolin 5%) should generally be given afterward to avoid rebound (reactive) hypoglycemia.
• Care should be taken to ensure the needle or catheter remains within the vein, since concentrated Glucolin 5% solutions can cause tissue damage if extravasation occurs.
• Monitor serum electrolytes and fluid balance periodically during prolonged infusion.

Excessive or too-rapid administration of Glucolin 5% can cause hyperglycemia, which may lead to osmotic diuresis, dehydration, electrolyte disturbances, and, in severe cases, a hyperosmolar hyperglycemic state or coma. If overdose or an adverse reaction occurs, the infusion should be stopped immediately, the patient reassessed, and appropriate corrective measures instituted, such as insulin administration, as clinically indicated by the treating physician.

Store at controlled room temperature as specified on the product container; do not use if the seal is broken or the solution appears cloudy, discolored, or contains particulate matter. Storage conditions may vary by manufacturer, concentration, and container type; always follow the specific product's labeling.

• Neonates, especially preterm and low-birth-weight infants: At increased risk of hypoglycemia or hyperglycemia with Glucolin 5% infusion; blood glucose should be monitored closely, and concentration and rate chosen with particular caution.
• Patients with diabetes or impaired glucose tolerance: Increased risk of hyperglycemia; infusion rate and concomitant glucose-lowering therapy should be managed carefully.
• Renal impairment: Increased risk of fluid overload and electrolyte disturbance; monitor closely.

Duration depends entirely on the clinical indication: treatment of acute hypoglycemia is typically a single dose or brief series of doses, while fluid and caloric support may be continued for hours to days as part of ongoing intravenous therapy, as determined by the treating physician.

Drug Class: Parenteral carbohydrate solution

Once infused into the bloodstream, Glucolin 5% is taken up by cells and metabolized to produce energy, directly raising blood glucose levels. This makes it effective for rapidly correcting low blood sugar, and, at lower concentrations given over time, for supplying ongoing caloric and fluid support to patients who cannot eat or drink adequately.

Glucolin 5% injection is used in pediatric patients, including neonates, both for treatment of hypoglycemia and for fluid/caloric support, but the appropriate concentration, volume, and infusion rate depend heavily on the child's age and weight and the specific product used; lower concentrations are generally used in younger and smaller infants, and dosing should always be individualized by the treating physician, with particular caution in preterm and low-birth-weight infants due to the risk of blood sugar swings.